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ABSTRACT
We studied platelet engraftment in 58 patients with acute myeloid leukemia in first remission treated with
autologous stem cell transplantation (ASCT) to determine whether CD34 cell doses >10  106/kg were
associated with faster platelet engraftment. We compared engraftment rates in patients receiving CD34 doses
between 5 and 10  106/kg (standard-dose ASCT) with those receiving doses >10  106/kg (high-dose [HD]
ASCT). We also studied neutrophil engraftment rates and platelet and red blood cell transfusion requirements.
In multivariate adjusted models, the rate of platelet recovery to>20,000/L was 4-fold greater among subjects
who received HD-ASCT (hazard ratio [HR], 4.1; confidence interval [CI], 1.8-9.2; P  .001), with median
recovery times of 14 versus 28 days. The rate of platelet recovery to >50,000/L was 2-fold greater (HR, 2.1;
CI, 1.3-5.9; P  .01), with median recovery times of 19 versus 46 days. Faster platelet recovery resulted in the
need for fewer platelet transfusions among the subjects who received HD-ASCT (mean transfusions, 3.7 versus
9.8; P  .005). Although not statistically significant, neutrophil recovery data in the adjusted model suggested
a similar effect in the HD-ASCT group, with faster engraftment times at absolute neutrophil counts >500/L
(median, 9.2 versus 12 days; HR, 1.6; CI, 0.69-3.5; P .29) and absolute neutrophil counts >1000/L (median,
9.5 versus 12 days; HR, 1.3; CI, 0.56-2.8; P  .58). Subjects who received HD-ASCT required fewer red blood
cell transfusions (4.0 versus 9.8 units; P  .01). Our findings suggest that CD34 cell doses >10  106/kg
CD34 result in faster engraftment and fewer red blood cell and platelet transfusions.
© 2003 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
The use of peripheral blood stem cells (PBSC)
ather than bone marrow has resulted in signiﬁcantly
aster hematopoietic engraftment during autologous
tem cell transplantation (ASCT) [1-3]. Faster en-
raftment has translated into less morbidity and mor-
ality and reduced use of resources such as hospital-
zation, antibiotics, and transfusions [2-9]. With
SCT, the dose of progenitor cells, as assayed by the
D34 antigen, has been shown to correlate with the
ate of neutrophil and platelet engraftment and the
eed for blood product transfusions [1,2,4-6,10-13].
ne large retrospective study demonstrated that a t
B&MTD34 cell dose 2.5  106/kg was adequate for
ngraftment [14], whereas others suggested that a
ose 5  106/kg was associated with improved time
o platelet recovery [8,15,16]. This latter dose has
ften been believed to be optimal [1,17], and it has
een proposed that doses above this threshold would
ot provide further beneﬁt. However, this question
as not been deﬁnitively studied.
We studied the use of ASCT as treatment for
cute myeloid leukemia (AML) in ﬁrst remission [18].
uring the early years of this study, the ability of
BSC to promote durable engraftment had not been
stablished in AML, and prior studies of bone marrowoi:10.1016/S1083-8791(03)00232-5ransplantation showed that patients with AML en-
643
grafted more slowly than patients with other diag-
noses. Because of this, there was concern that durable
engraftment from PBSC in patients with AML might
also be compromised, either because of the intensity
of prior therapy or because of abnormalities in bone
marrow biology related to the underlying disease.
Therefore, we initially harvested backup bone marrow
and attempted to collect a CD34 cell dose 10 
106/kg. After we documented consistent and sustained
engraftment with PBSC, we subsequently removed
the requirement for backup bone marrow and de-
creased the target CD34 cell dose to 5  106/kg.
This change in protocol design, with all other aspects
of the treatment held constant, gave us the opportu-
nity to evaluate whether a change in CD34 cell dose
affected the speed of platelet engraftment.
METHODS
Patients
Between May 1993 and November 1999, we
treated 67 patients with AML in ﬁrst remission in a
standardized protocol at the University of California
San Francisco. Eligible patients were initially between
the ages of 16 and 69 years. All patients were in their
ﬁrst remission with de novo AML and were eligible if
they were in complete remission for 30 days and 6
months. Complete remission was deﬁned by meeting
all of the following criteria: normal bone marrow
morphology with5% blasts, resolution of previously
abnormal cytogenetics, no evidence of extramedullary
leukemia, and an absolute neutrophil count (ANC)
500/L and platelet count 140,000/L.
Additionally, organ function needed to be ade-
quate, as demonstrated by the presence of the follow-
ing: bilirubin 1.5 mg/dL, alkaline phosphatase and
aspartate transaminase less than twice the upper limit
of normal, creatinine 2.0 mg/dL, cardiac ejection
fraction 40%, and a carbon monoxide diffusion ca-
pacity 50%. Exclusion criteria included prior myel-
odysplasia, myeloproliferative disease, or chemother-
apy-related leukemia. Patients who had received prior
postremission high-dose cytarabine were ineligible,
but patients may have received less intensive postre-
mission chemotherapy. All patients gave written, in-
formed consent in accord with the University of Cal-
ifornia San Francisco Committee on Human
Research.
Of the 67 patients originally enrolled in our pro-
spective cohort analysis, 2 patients were excluded be-
cause of incomplete records, and 7 were excluded
because of early relapse of AML. The remaining 58
patients were retrospectively divided into high-dose
(HD) and standard-dose (SD) ASCT recipients de-
pending on whether their CD34 cell dose was 5 to
9.9  106/kg or 10  106/kg.
The predictor variable in this study was CD34
cell dose during ASCT. The primary outcome was
time to platelet engraftment above threshold values of
20,000/L, 50,000/L, and 100,000/L. Secondary
outcomes included time to neutrophil engraftment
above ANC 500/L and ANC 1000/L and total
platelet and red blood cell (RBC) transfusion require-
ments. The time to platelet recovery was deﬁned as
the ﬁrst day of 2 contiguous platelet values above the
threshold value not dependent on platelet transfusion;
subsequent platelet measurements could not decrease
below the threshold value. Day 0 was deﬁned as the
day of transplantation.
Treatment
Patients received therapy in 2 sequential steps.
The ﬁrst step was consolidation chemotherapy with
cytarabine 2000 mg/m2 intravenously (IV) every 12
hours  8 doses on days 1 to 4 plus etoposide 40
mg/kg by continuous IV infusion over 96 hours on
days 1 to 4. Granulocyte colony-stimulating factor
(G-CSF) 5 g/kg/d subcutaneously was administered
from day 14 until completion of stem cell collection.
The G-CSF dose could be escalated to 10 g/kg/d if
stem cell collection was proceeding slowly. Stem cell
collection was initiated when the white blood cell
count was 10,000/L.
From 1993 to November 1996, the target harvest
dose of CD34 cells was 10  106/kg. Thereafter,
the target dose was reduced to 5  106/kg. Stem
cells were collected by apheresis; 18 L of blood was
processed daily. A buffy coat was prepared by centrif-
ugation and mixed in M199 media with 5% autolo-
gous plasma and 10% dimethyl sulfoxide to achieve a
ﬁnal cell concentration of 2.5 108 cells per milliliter.
The stem cell product was frozen in a controlled-rate
freezer and stored in liquid-phase liquid nitrogen.
After a rest period of at least 4 weeks (median, 6
weeks) after consolidation, patients were treated with
ASCT. The preparative regimen was busulfan 16
mg/kg orally (total dose) administered on days 7 to
4 plus etoposide 60 mg/kg IV over 10 hours on day
3. Unmanipulated stem cells were infused on day 0.
G-CSF 5 g/kg/d subcutaneously was given from day
0 until ANC was 1500/L for 2 days or 5000/L
for 1 day. Platelet transfusions were given if platelets
were 15,000/L in the presence of mucositis or
fever or 10,000/L in asymptomatic patients. Pa-
tients received RBC transfusions for a hematocrit
25%.
CD34 Assay
Cells were analyzed by ﬂow cytometry (FACScan;
Becton Dickinson, Franklin Lakes, NJ), and 75,000
CD45 events were collected for analysis by using the
International Society for Hematotherapy and Graft
Engineering protocol [19]. The total leukocyte count
was performed by using a standard hematology ana-
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lyzer (Cell Dyn 3500 or 4000; Abbott Laboratories,
Chicago, IL).
Statistical Analysis
We compared the baseline characteristics of
subjects who received HD-ASCT and SD-ASCT by
using unpaired t tests, Mann-Whitney tests, and 2
tests where appropriate. We compared the median
times to platelet recovery by using t tests or Mann-
Whitney tests, depending on the observed distribu-
tions of the data. We estimated the rates of platelet
recovery in the 2 groups by using the method of
Kaplan and Meier, and we tested for differences
between the 2 groups with the log-rank test [20,21].
We used Cox proportional hazards models [20,22]
to determine the association of stem cell dose with
platelet recovery, adjusting for potential confound-
ers, including age, sex, cytogenetics, all-trans reti-
noic acid–versus cytarabine-based induction regi-
men, platelet recovery times during consolidation,
and whether PBSC were harvested after November
1996. We tested for deviations from the assumption
of proportional hazards during follow-up [23,24],
and we found the assumption to be valid. All anal-
yses were performed with Stata 7.0 (Stata Corp.,
College Station, TX). Two-sided P values .05
were considered statistically signiﬁcant.
RESULTS
Patients
HD-ASCT patients received a median CD34
dose of 17  106/kg (range, 10-164  106/kg),
whereas SD-ASCT received a median CD34 dose of
6.6  106/kg (range, 4.2-9.6  106/kg; P  .001). We
identiﬁed no statistically signiﬁcant differences be-
tween the 2 groups in age, sex, cytogenetics (favorable,
intermediate, poor, and unknown), induction chemo-
therapy regimen, consolidation-phase platelet recov-
ery times, time from consolidation to harvest, time
from consolidation to transplantation, or whether har-
vest occurred after November 1996 (when the CD34
harvest goal was decreased from 10  106/kg to
5  106/kg; Table 1).
There were no clinically apparent retinal, neuro-
vascular, or gastrointestinal bleeding events in either
group. There were no signiﬁcant differences between
groups in the development or duration of neutropenic
fevers or the amount of prophylactic antibiotics used
for these periods. Time to discharge was not signiﬁ-
cantly different: 26 	 6.9 days in the HD-ASCT
Table 1. Patient Characteristics: n (%), Mean 	 SD, or Median (Range)
Characteristic
HD-ASCT* SD-ASCT*
P Value(N  48) (N  10)
Baseline
Age 42  13 37  9.8 .27
Male sex 20 (42) 3 (30) .49
Cytogenetics .27
Favorable 9 (19) 0 (0)
Intermediate 28 (58) 9 (90)
Poor 1 (2) 0 (0)
Unknown 10 (21) 1 (10)
Induction phase
Regimen† .50
High-dose cytarabine 30 (63) 7 (70)
Standard-dose cytarabine 12 (25) 3 (30)
All-trans retinoic acid 6 (13) 0 (0)
Consolidation phase
Days to platelets
>20000/L 26  8.8 31  9.6 .12
>50000/L 30  11 34  11 .33
>100000/L 46  54 40  22 .78
Days to start of stem cell collection 25  3.8 26  6.1 .31
Number of aphereses 2  1.7 2  2.9 .43
Days from consolidation to ASCT 47  15 50  27 .59
Harvest .16
Before November 1996 25 3
After November 1996 21 7
Transplantation phase
CD34 transplant dose 17 (10-164) 6.6 (4.2-9.6) .001
*SD-ASCT: CD34 5-9.9  106/kg; HD-ASCT: CD34  10  106/kg.
†High-dose cytarabine regimens included daunorubicin. Standard-dose cytarabine regimens included anthracycline. All-trans retinoic acid
regimens included either idarubicin or daunorubicin.
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645BB&MT
group versus 28 	 7.5 days in the SD-ASCT group
(P  .39).
Platelet and Neutrophil Engraftment
In unadjusted models, HD-ASCT was associated
with 3-fold faster platelet engraftment at
20,000/L and 2-fold faster engraftment at
50,000/L (Table 2; Figure 1). Our multivariate
adjusted model accounted for the following factors:
age, sex, cytogenetic risk group, induction chemother-
apy regimen, consolidation-phase platelet recovery
time, time between consolidation and harvest, and
whether harvest occurred after November 1996. In
the adjusted model, HD-ASCT was associated with a
4-fold faster rate of platelet recovery to 20,000/L
and a 2-fold faster rate of platelet recovery to
50,000/L, with median engraftment times of 14
versus 28 days (P  .001) and 19 versus 46 days (P 
.01) days, respectively (Table 2). There was suggestion
of faster recovery to platelets 100,000/L, with me-
dian recovery times of 29 versus 129 days, but there
was no statistically signiﬁcant difference between the
groups in either the adjusted or unadjusted models
(Table 2).
In the unadjusted model, HD-ASCT was associ-
ated with a statistically signiﬁcant 2-fold increase in
the neutrophil engraftment rate at ANC 500/L,
with median times of 9.2 versus 12 days (P  .048).
Although this was not statistically signiﬁcant, in the
adjusted model, HD-ASCT was associated with a
trend toward faster neutrophil engraftment at ANC
500/L and ANC 1000/L (Table 2).
Patients who received HD-ASCT required fewer
supportive blood product transfusions. Mean platelet
transfusions were lower in the HD-ASCT group, at
3.7 	 2.5 versus 9.8 	 3.3 (P  .005). Mean RBC
transfusion requirements were lower in the HD-
ASCT group, at 4.0 	 2.9 versus 9.8 	 15 (P  .01).
There was no statistically signiﬁcant difference in
event-free survival (EFS) between patients who re-
ceived HD-ASCT and SD-ASCT, with 6-year EFS
rates of 61% versus 56%, respectively. When patients
with acute promyelocytic leukemia are excluded (all of
whom were in the HD-ASCT group), the EFS is 51%
versus 56% (P  .74).
DISCUSSION
In this study, we found that subjects with AML
who received HD-ASCT (CD34 cell dose 10 
106/kg) had faster engraftment of platelets than pa-
tients who received SD-ASCT (CD34 cell doses
between 5 and 9.9  106/kg). The differences were
both statistically signiﬁcant and clinically relevant,
with a 2-week reduction in the time to platelets
20,000/L and a 4-week reduction in time to plate-
let recovery 50,000/L. Faster platelet recovery re-
sulted in 6 fewer platelet transfusions. HD-ASCT
patients also showed a trend toward faster neutrophil
recovery—3 days faster to ANC 500/L and to
ANC 1000/L—and required 6 fewer units of
transfused RBCs.
Other studies have generally shown an inverse
correlation between the CD34 dose and hematopoi-
etic engraftment rate [1,2,4-6,10-13]. However, poor
interinstitution CD34 assay reproducibility makes the
validity of analysis of pooled data uncertain [19,25]. In
addition, previous studies suggest that factors such as
differing forms of chemotherapy and conditioning
regimens [1,13,26,27] and having received a prior
bone marrow transplantation [4] may affect engraft-
ment rates. Finally, different types of cancer may af-
fect posttransplantation platelet recovery times
[27,28]. Therefore, extrapolation of these previously
described dose-response relationships to the use of
HD-ASCT in AML may not be valid.
Table 2. CD34 Cell Dose and Engraftment Kinetics
Variable
Unadjusted
Multivariate-Adjusted*Median Days to Recovery after
ASCT: Median (Range) or
Mean  SD
Hazard Ratio
(95% CI) P Value
Hazard Ratio
(95% CI) P ValueHD-ASCT† SD-ASCT†
Platelet recovery
>20000/L 14 (0-90) 28 (15-190) 3.5 (1.7-7.4) .001 4.1 (1.8-9.2) .001
>50000/L 19 (8-193) 46 (21-190) 2.5 (1.3-5.1) .01 2.1 (1.3-5.9) .01
>100000/L 29 (9-448) 129 (28-330) 1.5 (0.7-3.2) .30 1.3 (0.55-2.9) .59
ANC recovery
>500/L 9.2  1.0 12  5.2 2.1 (1.0-4.5) .048 1.6 (0.69-3.5) .29
>1000/L 9.5  1.2 12  5.6 1.8 (0.84-3.8) .14 1.3 (0.56-2.8) .58
Platelet transfusions 3.7  2.5 9.8  3.3 .005
RBC transfusions 4.0  2.9 9.8  15 .01
CI indicates conﬁdence interval.
*Hazard ratios were adjusted for age, sex, cytogenetics proﬁle, induction chemotherapeutic regimen, consolidation-phase platelet recovery
times, time from consolidation to harvest, and whether cells were harvested after November 1996.
†SD-ASCT: CD34 5-9.9  106/kg; HD-ASCT: CD34 10  106/kg.
N. Gunn et al.
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In this study, we examined a speciﬁc, relatively
homogeneous patient cohort: patients with AML in
ﬁrst remission who were treated with uniform therapy
(after remission induction) at a single institution. We
accounted for possible confounders with multivariate
regression analysis. Variables included age, sex, cyto-
genetic risk group, remission induction chemotherapy
regimen, and time between consolidation and harvest.
We also controlled for platelet engraftment time dur-
ing consolidation, because a slow pretransplantation
platelet recovery rate may have been a marker for a
poor marrow microenvironment. Finally, because the
CD34 cell dose requirement was decreased after
November 1996, we controlled for whether the har-
vest occurred after this time point. This controlled for
those who had a CD34 cell dose 10  106/kg by
design (ie, cells were harvested after November 1996
with a goal CD34 of 5  106/kg) versus those who
could not reach a threshold of 10  106/kg because of
poor stem cell mobilization (n  3) before November
1996. Our data, adjusted for these variables, demon-
strate that infused CD34 cell doses 10  106/kg
are associated with faster engraftment.
Our study had a relatively small number of pa-
tients. Although this does not affect the positive re-
sults of this study, the lack of signiﬁcance in negative
results may be a result of low power. For example,
there may be some survival advantage to high-dose
transplantation because of decreased amounts of
thrombocytopenic-associated complications; con-
Figure 1. Kaplan-Meier cumulative probability curves illustrating the time to platelet recovery to 20,000/L, 50,000/L, and
100,000/L for high-dose versus standard-dose autologous stem cell transplantation (HD-ASCT and SD-ASCT, respectively). In the
adjusted model, HD-ASCT was associated with faster platelet engraftment to 20,000/L (P  .001) and to 50,000/L (P  .01), but not to
100,000/L (P  .59).
High CD34 Dose
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versely, high-dose harvesting may result in the trans-
plantation of higher numbers of tumor cells, leading
to higher rates of relapse. Such outcomes may become
manifest only in a study with increased power. Nev-
ertheless, no differences were found between groups
in the EFS rates or in the number of morbid compli-
cations of prolonged thrombocytopenia.
Our ﬁndings offer evidence that ASCT with
CD34 cell doses 10  106/kg is associated with
faster platelet engraftment that is clinically meaning-
ful and results in decreased need for transfusion of
platelets and RBCs. In addition, the ability to achieve
rapid and sustained platelet engraftment early after
transplantation may facilitate the use of posttransplan-
tation therapies such as tumor vaccines and interleu-
kin-2, which are generally started when adequate lev-
els of blood count recovery have occurred.
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